X

Health & Biotech

Nanollose enters Paradise with forest-friendly Nullarbor fibre collab

Special Report: Nanollose has signed another key collaboration agreement as interest continues to grow in its eco-friendly microbial cellulose-based technology.

PharmAust inks deal with Radium Capital to bag up-front R&D tax claim

Special Report: PharmAust will get early access to its FY22 R&D Tax Incentive amount, estimated at ~$210k, strengthening its financial…

ASX Health Stocks: Nyrada gets closer to European patent, and HOPE for Zelira’s autism tincture

Nyrada's European patent submission gets a patent number Zelira's positive study results on its autism tincture, HOPE  Beamtree gives beaming…

CRITERION: Are the thrills worth the spills on the small cap rollercoaster right now? Maybe…

While small caps are sold off faster than the larger stocks, the corollary is that they can do better in…

ASX Health Stocks: GTG set to jump into online after buying ecommerce outfit AffinityDNA

Genetic Technologies buys out ecommerce company, AffinityDNA Regis Healthcare says it expects to be fully reimbursed by the government for…

PharmAust set for Phase 1 Motor Neurone Disease trial as Monepantel tablets arrive

Special Report: The much anticipated Phase 1 clinical trial of PharmAust’s lead asset Monepantel on patients with Motor Neurone Disease…

ASX Health Stocks: Cancer fighter Amplia will start Phase 2 trial after getting final ethics approval

ASX health stock Amplia has received a second ethics approval, and can start Phase 2 of the AMP945 trial to…

Stock Insiders: NGS are reaching new heights with a clinically tested nutritional supplement

Nutritional Growth Solutions is a global nutritional health company, working to ensure children reach their potential height.

Incannex shares reach a high of 44c on landmark $125m deal to buy US cannabinoid pioneer APIRx

Special Report: Incannex shares have rocketed higher today on news it has signed a formal deal to buy out APIRx…

ASX Health Stocks: Race and Rhythm make their moves to advance Australian share

ASX health stock Race Oncology has been given governance approval for the lead site of its clinical trial of Zantrene…

Check Up: Is biotech a good investment in a higher rate cycle? Turns out theory is just a theory

A study explores the correlation between higher rates and biotech stock prices And also High Cap vs Low Cap biotechs…

PharmAust expands canine trial of Monepantel to the US, expediting the close out of Phase 2 study

Special Report: The expansion of the canine trial of Monepantel to the US comes after successful earlier trials in both…

ASX Health Stocks: Integral goes big in Queensland, Credit Suisse says it’s time to choose between HLS and ACL

IDX snaps up QLD-based radiology group for circa $38m, NSB starts HREC review process, and Credit Suisse downgrades HLS.

Bone specialist Osteopore secures key ANZ distribution as it targets oral & maxillofacial surgery

Special Report: Osteopore has signed a key distribution deal in Australia and New Zealand as it moves to gain a…

Knocking heads: Incannex achieves key concussion breakthrough

Special Report: IHL’s novel drug IHL-216A could be the holy grail in concussion treatment, with promising preclinical study results showing…

ASX Health Stocks: Ecstasy for Emyria in MDMA trial, Beamtree wins US$7m deal

Emyria announced progress on its MDMA (ecstasy) program Imugene gets green light for a Phase 2 Australian clinical trial Beamtree…